Figures
Are drug companies living up to their human rights responsibilities?
This month PLoS Medicine publishes a Debate that offers three unique perspectives on this question: Sofia Gruskin and Zyde Raad from the Harvard School of Public Health say more assessment is needed of such responsibilities; Geralyn Ritter, Vice President of Global Public Policy and Corporate Responsibility at Merck & Co. argues that multiple stakeholders could do more to help States deliver the right to health; and Paul Hunt and Rajat Khosla introduce Mr. Hunt's work as the UN Special Rapporteur on the right to the highest attainable standard of health (2002-2008), regarding the human rights responsibilities of pharmaceutical companies and access to medicines. In their accompanying Editorial, the PLoS Medicine Editors argue that drug companies should be held much more accountable for their human rights responsibilities.
Image Credit: cosmo flash (at flickr.com)
Citation: (2010) PLoS Medicine Issue Image | Vol. 7(9) September 2010. PLoS Med 7(9): ev07.i09. https://doi.org/10.1371/image.pmed.v07.i09
Published: September 28, 2010
Copyright: © 2010 cosmo flash. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This month PLoS Medicine publishes a Debate that offers three unique perspectives on this question: Sofia Gruskin and Zyde Raad from the Harvard School of Public Health say more assessment is needed of such responsibilities; Geralyn Ritter, Vice President of Global Public Policy and Corporate Responsibility at Merck & Co. argues that multiple stakeholders could do more to help States deliver the right to health; and Paul Hunt and Rajat Khosla introduce Mr. Hunt's work as the UN Special Rapporteur on the right to the highest attainable standard of health (2002-2008), regarding the human rights responsibilities of pharmaceutical companies and access to medicines. In their accompanying Editorial, the PLoS Medicine Editors argue that drug companies should be held much more accountable for their human rights responsibilities.
Image Credit: cosmo flash (at flickr.com)